Knight Therapeutics Inc
OTC:KHTRF
Relative Value
The Relative Value of one KHTRF stock under the Base Case scenario is hidden USD. Compared to the current market price of 4.33 USD, Knight Therapeutics Inc is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
KHTRF Competitors Multiples
Knight Therapeutics Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
K
|
Knight Therapeutics Inc
OTC:KHTRF
|
582.1m USD | 1.4 | -166.7 | 12.5 | -47.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD | 15.3 | 48.3 | 32.5 | 34.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF | 4.6 | 29.9 | 12.7 | 14.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD | 4.7 | 16.6 | 10.4 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF | 5.3 | 21.3 | 13.2 | 16.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP | 5.3 | 32.5 | 15.5 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 4.6 | 13.9 | 10.1 | 11.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD | 2.5 | 19.9 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD | 2.6 | 17.8 | 6.9 | 8.9 |